FibroBiologics Completes Third cGMP CYWC628 Batch, Ensuring Full Trial Supply
FBLG•FibroBiologics has finished manufacturing its third cGMP batch of CYWC628 for its Phase 1/2 diabetic foot ulcer trial, ensuring sufficient drug product to complete the study. This eliminates further vial production, cuts manufacturing cash outlays and positions the company to report interim Phase 1/2 data in Q3 2026.
1. Third Batch Manufacturing Completed
FibroBiologics has completed GMP-compliant manufacturing of the third CYWC628 drug product batch for its ongoing Phase 1/2 diabetic foot ulcer trial. The batch is currently undergoing required safety and quality testing ahead of release for clinical use.
2. Trial Supply and Cost Savings
The third batch provides sufficient product to complete the DFU clinical study without the need for additional vial production, eliminating short-term manufacturing expenses. Surplus doses generated by this process are available for future research and development initiatives.
3. Upcoming Interim Data in Q3 2026
The company expects to report statistically significant interim data from the Phase 1/2 diabetic foot ulcer trial in Q3 2026, which will inform efficacy assessments and guide potential next-phase clinical designs.
